Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Invida Group is set to introduce Atopiclair for the treatment of atopic dermatitis symptoms, in Asia in the second half of 2011.
Subscribe to our email newsletter
The data from randomized, double blind, controlled multi-center clinical trials of Atopiclair in adults, children and, infants aged over 6 months, showed relief and control of the symptoms linked with atopic dermatitis with safety and effective profile.
Invida Group CEO John Graham said to make Atopiclair available across Asia is an important achievement, as it has proven to be such an effective treatment for the painful effects of atopic dermatitis in other parts of the world.
Invida Korea Country Manager Mark Brown said tthey believe that Atopiclair will be a significant treatment to help patients and their families better manage the debilitating symptoms of atopic dermatitis.